Do analysts recommend RFAI or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, RFAI or TAOX?

RF Acquisition Corp II has higher earnings, but lower revenue than Synaptogenix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A Synaptogenix $300K 107.26 -$28.74M -$3.85 N/A

Do analysts rate TAOX or VANI?

Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 207.38%. Given Vivani Medical's stronger consensus rating and higher possible upside, analysts plainly believe Vivani Medical is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer TAOX or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, TAOX or RFL?

Synaptogenix has higher earnings, but lower revenue than Rafael. Rafael is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synaptogenix $300K 107.26 -$28.74M -$3.85 N/A Rafael $980K 107.24 -$30.52M -$0.68 N/A

Is TAOX or RFL more profitable?

Synaptogenix has a net margin of -2,153.97% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix -2,153.97% -128.51% -97.54% Rafael -3,321.74% -41.27% -35.32%

Do analysts recommend TAOX or PLYX?

Polaryx Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 251.68%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Do analysts rate PYPD or TAOX?

PolyPid presently has a consensus target price of $11.33, indicating a potential upside of 114.85%. Given PolyPid's stronger consensus rating and higher probable upside, analysts plainly believe PolyPid is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PYPD or TAOX more profitable?

PolyPid has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Synaptogenix -2,153.97% -128.51% -97.54%

Synaptogenix (TAOX) Competitors

$4.30 -0.02 (-0.42%)

As of 09:41 AM Eastern

Compare

TAOX vs. RFAI, VANI, RFL, PLYX, and PYPD

Should you buy Synaptogenix stock or one of its competitors? Synaptogenix's main competitors and comparable companies include RF Acquisition Corp II (RFAI), Vivani Medical (VANI), Rafael (RFL), Polaryx Therapeutics (PLYX), and PolyPid (PYPD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Synaptogenix compare to RF Acquisition Corp II?

RF Acquisition Corp II (NASDAQ:RFAI) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, RF Acquisition Corp II had 1 more articles in the media than Synaptogenix. MarketBeat recorded 1 mentions for RF Acquisition Corp II and 0 mentions for Synaptogenix. RF Acquisition Corp II's average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Company	Overall Sentiment
RF Acquisition Corp II	Neutral
Synaptogenix	Neutral

RF Acquisition Corp II has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

10.3% of Synaptogenix shares are held by institutional investors. 39.1% of RF Acquisition Corp II shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

RF Acquisition Corp II has higher earnings, but lower revenue than Synaptogenix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
Synaptogenix	$300K	107.26	-$28.74M	-$3.85	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RF Acquisition Corp II has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. RF Acquisition Corp II's return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
Synaptogenix	-2,153.97%	-128.51%	-97.54%

Summary

RF Acquisition Corp II beats Synaptogenix on 5 of the 8 factors compared between the two stocks.

How does Synaptogenix compare to Vivani Medical?

Synaptogenix (NASDAQ:TAOX) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Vivani Medical has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Vivani Medical	N/A	-191.05%	-70.91%

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 207.38%. Given Vivani Medical's stronger consensus rating and higher possible upside, analysts plainly believe Vivani Medical is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Vivani Medical'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Vivani Medical	Neutral

Vivani Medical has lower revenue, but higher earnings than Synaptogenix. Vivani Medical is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	107.26	-$28.74M	-$3.85	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Synaptogenix has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market.

Summary

Vivani Medical beats Synaptogenix on 9 of the 13 factors compared between the two stocks.

How does Synaptogenix compare to Rafael?

Synaptogenix (NASDAQ:TAOX) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Rafael	Neutral

Synaptogenix has higher earnings, but lower revenue than Rafael. Rafael is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	107.26	-$28.74M	-$3.85	N/A
Rafael	$980K	107.24	-$30.52M	-$0.68	N/A

Synaptogenix has a net margin of -2,153.97% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Rafael	-3,321.74%	-41.27%	-35.32%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synaptogenix has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Rafael has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Summary

Rafael beats Synaptogenix on 6 of the 11 factors compared between the two stocks.

How does Synaptogenix compare to Polaryx Therapeutics?

Synaptogenix (NASDAQ:TAOX) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Polaryx Therapeutics has lower revenue, but higher earnings than Synaptogenix. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	107.26	-$28.74M	-$3.85	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Polaryx Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 251.68%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Polaryx Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Polaryx Therapeutics	Neutral

10.3% of Synaptogenix shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Polaryx Therapeutics beats Synaptogenix on 10 of the 13 factors compared between the two stocks.

How does Synaptogenix compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

PolyPid presently has a consensus target price of $11.33, indicating a potential upside of 114.85%. Given PolyPid's stronger consensus rating and higher probable upside, analysts plainly believe PolyPid is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PolyPid has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

PolyPid has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

In the previous week, PolyPid had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for PolyPid and 0 mentions for Synaptogenix. PolyPid's average media sentiment score of 0.61 beat Synaptogenix's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Positive
Synaptogenix	Neutral

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Synaptogenix has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Synaptogenix	$300K	107.26	-$28.74M	-$3.85	N/A

Summary

PolyPid beats Synaptogenix on 9 of the 15 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAOX vs. The Competition

Export

Metric	Synaptogenix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.13M	$12.59B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.56%
P/E Ratio	-1.12	792.28	274.07	25.70
Price / Sales	107.26	857.34	673.22	90.62
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.52	10.58	10.38	6.32
Net Income	-$28.74M	$2.81B	$3.49B	$359.73M
7 Day Performance	5.44%	-0.16%	-0.69%	0.17%
1 Month Performance	10.03%	-1.38%	-3.19%	-3.27%
1 Year Performance	-27.82%	2.83%	15.12%	5.58%

Synaptogenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAOX Synaptogenix	0.0865 of 5 stars	$4.30 -0.4%	N/A	-24.1%	$32.13M	$300K	N/A	4	Gap Down
RFAI RF Acquisition Corp II	0.928 of 5 stars	$32.30 +7.3%	N/A	+221.6%	$115.93M	N/A	N/A	N/A	Gap Down
VANI Vivani Medical	2.4844 of 5 stars	$1.26 -1.2%	$3.75 +198.8%	-18.0%	$113.20M	N/A	N/A	20	Positive News
RFL Rafael	0.1345 of 5 stars	$2.18 -4.5%	N/A	+38.8%	$112.84M	$920K	N/A	20	Gap Up
PLYX Polaryx Therapeutics	2.6064 of 5 stars	$2.04 +1.2%	$7.67 +276.7%	N/A	$101.45M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TAOX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synaptogenix (TAOX) Competitors

TAOX vs. RFAI, VANI, RFL, PLYX, and PYPD

How does Synaptogenix compare to RF Acquisition Corp II?

Summary

How does Synaptogenix compare to Vivani Medical?

Summary

How does Synaptogenix compare to Rafael?

Summary

How does Synaptogenix compare to Polaryx Therapeutics?

Summary

How does Synaptogenix compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synaptogenix (TAOX) Competitors

TAOX vs. RFAI, VANI, RFL, PLYX, and PYPD

How does Synaptogenix compare to RF Acquisition Corp II?

Does the media refer more to RFAI or TAOX?

Which has more risk and volatility, RFAI or TAOX?

Do insiders and institutionals believe in RFAI or TAOX?

Which has stronger valuation & earnings, RFAI or TAOX?

Do analysts recommend RFAI or TAOX?

Is RFAI or TAOX more profitable?

Summary

How does Synaptogenix compare to Vivani Medical?

Is TAOX or VANI more profitable?

Do insiders & institutionals hold more shares of TAOX or VANI?

Do analysts rate TAOX or VANI?

Does the media prefer TAOX or VANI?

Which has better earnings and valuation, TAOX or VANI?

Which has more volatility & risk, TAOX or VANI?

Summary

How does Synaptogenix compare to Rafael?

Do insiders and institutionals have more ownership in TAOX or RFL?

Does the media prefer TAOX or RFL?

Which has better valuation & earnings, TAOX or RFL?

Is TAOX or RFL more profitable?

Do analysts prefer TAOX or RFL?

Which has more risk and volatility, TAOX or RFL?

Summary

How does Synaptogenix compare to Polaryx Therapeutics?

Which has stronger earnings & valuation, TAOX or PLYX?

Do analysts recommend TAOX or PLYX?

Is TAOX or PLYX more profitable?

Does the media prefer TAOX or PLYX?

Do insiders & institutionals hold more shares of TAOX or PLYX?

Summary

How does Synaptogenix compare to PolyPid?

Do analysts rate PYPD or TAOX?

Which has more risk & volatility, PYPD or TAOX?

Is PYPD or TAOX more profitable?

Does the media favor PYPD or TAOX?

Do institutionals and insiders believe in PYPD or TAOX?

Which has higher earnings and valuation, PYPD or TAOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools